Abstract
Background
Carbohydrate antigen 19–9 (CA19-9) is the most widely used biomarker for pancreatic cancer. Since CA19-9 closely correlates with patient outcome and tumor stage in pancreatic cancer, the deciphering of CA19-9 biosynthesis provides a potential clue for treatment.
Methods
Concentration of amino acids was detected by ultrahigh-performance liquid chromatography tandem mass spectrometry. Metabolic flux of glutamine was examined by isotope tracing untargeted metabolomics. Label-free quantitative n-glycosylation proteomics was used to examine n-glycosylation alterations.
Results
Among all amino acids, glutamine was higher in CA19-9-high pancreatic cancers (> 37 U/mL, 66 cases) than in CA19-9-normal clinical specimens (≤ 37 U/mL, 37 cases). The glutamine concentration in clinical specimens was positively correlated with liver metastasis or lymphovascular invasion. Glutamine blockade using diazooxonorleucine suppressed pancreatic cancer growth and intraperitoneal and lymphatic metastasis. Glutamine promotes O-GlcNAcylation, protein glycosylation, and CA19-9 biosynthesis through the hexosamine biosynthetic pathway. UDP-n-acetylglucosamine (UDP-GlcNAc) levels correlated with the glutamine influx through hexosamine biosynthetic pathway and supported CA19-9 biosynthesis.
Conclusions
Glutamine is a substrate for CA19-9 biosynthesis in pancreatic cancer. Glutamine blockade may be a potential therapeutic strategy for pancreatic cancer.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
1 Introduction
Pancreatic ductal adenocarcinoma (PDAC), a major form of pancreatic cancer, is a highly lethal carcinoma with a mortality almost equal to its incidence [1]. There are no methods for early detection; as a result, only approximately 20% of patients with pancreatic cancer have the opportunity to receive surgical resection, which provides the only chance of cure. Although major advances in cancer treatment have been made in the recent past, the outcome of pancreatic cancer has only modestly improved [2].
A distinct pathologic trait for pancreatic cancer is extensive desmoplasia, which accounts for approximately 80% of the tumor mass [3]. There is still an intense dispute concerning whether stroma promotes or prevents the development of pancreatic cancer [3]. An interconversion between collagen and glutamine through proline is well recognized, and the direction mainly depends on the tumor microenvironment and genetic alterations such as MYC and KRAS [4].
Sialyl Lewis a (CA19-9), also called carbohydrate antigen 19–9 is the most widely used and best validated biomarker for the management of pancreatic cancer [5]. Approximately 80% of pancreatic cancer patients have elevated levels of circulating CA19-9, and the level of CA19-9 is positively correlated with tumor burden and stage. As a biomarker, CA19-9 could be employed to evaluate tumor stage, assess prognosis and resectability, and monitor therapeutic response [5]. Recent studies have shown that CA19-9 is not merely a “bystander” but may actively participate in the progression of pancreatic cancer [6, 7].
Metabolic reprogramming has long been recognized as an emerging hallmark of cancer [8]. Glutamine, a nonessential amino acid, is the most abundant amino acid in the circulation of the human body [9]. Most types of cancer have a strong metabolic dependency to glutamine for development [10]. Glutamine is a super nutrient that supplies fuel for energy production and biosynthesis of lipids, glucose, and nucleotides mainly through the tricarboxylic acid (TCA) cycle [10, 11]. Pancreatic cancer cells, which reside in a harsh and nutrient-poor microenvironment, have a particular requirement for glutamine for progression [8, 12]. However, the connections between glutamine and clinical relevance or CA19-9 production have not been explored.
2 Results
2.1 Glutamine levels are positively correlated with aggressive clinical characteristics and CA19-9
CA19-9 has been reported to be the best-validated biomarker in pancreatic cancer, which is closely correlated with patient outcome and tumor stage [5, 13]. By analyzing 1028 patients with pancreatic cancer, we confirmed that CA19-9 elevation was an adverse prognostic predictor (Fig. 1A) and that the level of CA19-9 was positively correlated with tumor stage (Fig. 1B). To screen amino acids that may play a key role in tumor progression and CA19-9 biosynthesis, the concentration of amino acids in clinical specimens was analyzed by ultrahigh-performance liquid chromatography tandem mass spectrometry (UHPLC–MS/MS). Glutamine was higher in CA19-9-high pancreatic cancers (> 37 U/mL, 66 cases) than in CA19-9-low specimens (≤ 37 U/mL, 37 cases; Fig. 1C). The level of glutamine in pancreatic cancers was lower than that in paracancer tissues and higher than that in pancreatic neuroendocrine neoplasms (Fig. 1D, E). This observation indicates that paracancer tissues may provide glutamine for pancreatic cancer cells progression. Interestingly, primary pancreatic cancers had a lower concentration of glutamine than their matched liver metastases (Fig. 1F, G). Moreover, glutamine was more abundant in pancreatic cancers with lymphovascular invasion than in those without (Fig. 1H, I). These findings confirm that pancreatic cancer cells have strong dependence on glutamine for growth/invasion/metastasis and are consistent with the observation that the concentration of glutamine in pancreatic cancer was correlated positively with CA19-9. Taken together, these results indicate that glutamine is positively correlated with aggressive clinical characteristics in pancreatic cancer.
2.2 Glutamine promotes pancreatic cancer growth and metastasis
Pancreatic cancer cells have a strong need for glutamine, which is a substrate to support anabolic processes that fuel proliferation [14]. Moreover, glutamine metabolism also plays an active role in the invasive potential of pancreatic cancer [15]. In this study, the proliferation of pancreatic cancer cells (SW1990, BxPC-3, and SU.8686) at different time points with and without 2 mM glutamine was determined by CCK-8 and colony formation assays. Glutamine promoted the proliferation of all pancreatic cancer cells (Fig. 2A, C). Moreover, glutamine enhanced colony formation in different pancreatic cancer cells (Fig. 2D–F). Colonies were less formed in pancreatic cancer cells cultured for two weeks in the absence of glutamine. Therefore, glutamine is an essential nutrient for the progression of pancreatic cancer. Diazooxonorleucine (Don), an inhibitor of glutamine, inhibited tumor growth (Fig. 2G–J) in subcutaneous mouse models of pancreatic cancer. Don also suppressed lymphatic metastasis (Fig. 2K, L) in footpad mouse models and peritoneal seeding (Fig. 2M, N) in peritoneal mouse models. The decrease in metastasis may be a result of the inhibition of the growth and viability of pancreatic cancer cells using Don. Thus, glutamine not only provides substrates for biosynthesis but also contributes to the metastasis of pancreatic cancer cells.
2.3 Metabolic flux of glutamine in pancreatic cancer cells
To examine the metabolic flux of glutamine in pancreatic cancer cells, C or N isotope labelled glutamine was traced in SU.8686 cells cultured for 12 h and 24 h by isotope tracing untargeted metabolomics using ultrahigh-performance liquid chromatography coupled with tandem Q-Exactive Orbitrap mass spectrometry (UHPLC-MS; Fig. 3A). In addition to its well-recognized role in the TCA cycle, cell division, and reactive oxygen species (ROS) reactions, glutamine also contributes to the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc) and UDP-N-acetyl-D-galactosamine (UDP-GalNAc), critical substrates for glycosylation. Moreover, isotopes were detected in proline, 5-oxoproline, and 5-oxo-D-proline, which have a close relationship with collagen and stroma formation. Notably, the metabolic flow of glutamine in cancer cells is influenced by the tumor microenvironment. In a MYC-inducible human Burkitt lymphoma model P493 cell line, glutamine entered the TCA cycle and contributed to citrate carbons under hypoxia and to fumarate, malate, and citrate under glucose deprivation [16].
2.4 Glutamine promotes O-GlcNAcylation
Glutamine acts as a major substrate for the hexosamine biosynthetic pathway (HBP), an important branch of glycolysis [10]. UDP-GlcNAc, the end-product of HBP, is a critical metabolite used for O-GlcNAcylation as well as for O- and N-glycosylation [17]. O-GlcNAcylation is the covalent attachment of GlcNAc to serine or threonine residues of nuclear and cytoplasmic proteins and is an important posttranslational modification [18]. It plays a key role in cancer-related activities, such as tumor proliferation, cell signaling, metabolism, invasion and metastasis [18]. In this study, we demonstrated that glutamine enhanced O-GlcNAcylation in pancreatic cancer cells (SW1990, BxPC-3, SU.8686) using immunofluorescence confocal microscopy (Fig. 4A, B). The effect of glutamine promoting O-GlcNAc biosynthesis was confirmed using western blotting after cells were cultured in different concentrations of glutamine (Fig. 4C). Glutamine inhibitors (Don and azaserine) decreased the biosynthesis of O-GlcNAc in pancreatic cancer cells (Fig. 4D). The correlation between glutamine and O-GlcNAc expression was confirmed in clinical pancreatic cancer samples (Fig. 4E, F). Isotope labeled glutamine could be traced in UDP-GlcNAc using UHPLC-MS (Fig. 4G). Thus, glutamine promotes O-GlcNAc biosynthesis in pancreatic cancer.
2.5 Glutamine enhances glycosylation
Glycosylation, a process related to the production of glycosidic linkages of saccharides to proteins, lipids, or other saccharides, is widely present in normal cells and regulates fundamental physiological processes [19]. Compared with their non-transformed counterparts, cancer cells generally augment the degree of glycosylation. The function of glycosylation in cancers includes tumor proliferation, invasion and metastasis, cell‒cell communication, signal transduction, and extracellular matrix formation [20]. Aberrant N-linked glycosylation is quite apparent in pancreatic cancer and can be observed by the most widely used serological marker of CA19-9, which contains a glycan known as sialyl Lewis a. In this study, lectin blotting showed that DSL, PHA-E, AAL, and PHA-L were upregulated in cells cultured with glutamine-containing media (Fig. 5A). In addition to UDP-GlcNAc, UDP-GalNAc, an interconverted product of UDP-GlcNAc, could be traced by UHPLC-MS when cells were cultured in isotope-labeled glutamine (Fig. 5B), suggesting that glutamine is a substrate for glycosylation. By comparing N-glycosylation alterations between high- and low-glutamine pancreatic cancers in clinical specimens using label-free quantitative proteomics, cancer-related pathways, including PI3K-Akt signaling, ECM-receptor interaction, and cell adhesion, were identified (Fig. 5C, D). Protein‒protein interactions, including TGFB2, SLC2A1, INSR, LAMB1, ITGA2, ITGA3, ICAM1, CD274, THBS4, and CD36, were observed (Fig. 5E). Taken together, glutamine exacerbated glycosylation modification in pancreatic cancer cells.
2.6 Glutamine is a substrate for CA19-9 biosynthesis
CA19-9 is the most widely used biomarker for pancreatic cancer [5, 20]. Accordingly, understanding the biosynthesis of CA19-9 may provide a potential solution for the treatment of pancreatic cancer. To confirm the connection between glutamine and CA19-9 biosynthesis, the impact of glutamine on CA19-9 biosynthesis was evaluated in vitro and in clinical samples. Glutamine supplementation increased the levels of CA19-9 in SW1990, BxPC-3, and SU.8686 cells (Fig. 6A, C) and their supernatant (Fig. 6E) cultured for 72 h. The effect of glutamine promoting CA19-9 biosynthesis was also present when pancreatic cancer cells were cultured for 48 h (Fig. 6D). Don and azaserine, two glutaminase inhibitors, decreased the level of CA19-9 in pancreatic cancer cells (Fig. 6C, E).
To examine the impact of glutamine blockade on CA19-9 levels, both subcutaneous and footpad mice models established by SW1990 and BxPC-3 cells were used. Tumor content of CA19-9 was evaluated by immunofluorescence and serum concentration of CA19-9 was examined by electrochemiluminescence immunoassay. Don inhibited tissue (Fig. 7A–D) and serum content (Fig. 7E–H) of CA19-9 in subcutaneous and footpad mice models. Since the type I chain (Gal-GlcNAc) is the backbone structure of CA19-9 [6], we propose that glutamine is a substrate for CA19-9 biosynthesis and UDP-GlcNAc, the end-product of the hexosamine biosynthetic pathway, is an intermediate product between glutamine and CA19-9 (Fig. 7I).
3 Discussion
Pancreatic cancer cells have a strong dependence on glutamine for growth and metastasis [11, 21]. In this study, we demonstrated that glutamine was rich in highly aggressive and glycosylated pancreatic cancers. The glutamine concentration in clinical tissues was associated with liver metastasis or lymphovascular invasion. Glutamine promotes O-GlcNAcylation, protein glycosylation, and CA19-9 biosynthesis through the hexosamine biosynthetic pathway. Thus, glutamine promotes pancreatic cancer progression and O-GlcNAcylation (Fig. 7I).
Our study suggests that glutamine promotes tumor progression and CA19-9 biosynthesis in pancreatic cancer. Overall, glutamine promotes pancreatic cancer progression by ATP generation, biomass production, and signal transduction [10]. It is a major source of energy and nitrogen for biosynthesis and a carbon substrate for anabolic processes in cancer cells. However, the role of glutamine in signal transduction has largely been neglected. In this study, we found that glutamine can enhance CA19-9 production and glycosylation. Taken together, glutamine plays a comprehensive role in pancreatic cancer progression.
The concept of glutamine restriction for the treatment of cancers has existed for a long time [9, 11]. The translational value for pancreatic cancer is strengthened by our study, which connects glutamine with CA19-9 biosynthesis. Dietary modification of the host has a major impact on the availability of glutamine in the tumor microenvironment and thereby the progression of pancreatic cancer [22]. Importantly, glutamine limitation may have a synergistic effect on other therapeutic methods. For example, a glutamine restriction diet has been reported to improve the survival of medulloblastoma animal models, and this effect could be strengthened when combined with cisplatin chemotherapy [23].
Although our report suggests that glutamine promotes pancreatic cancer progression and CA19-9 biosynthesis, a therapeutic strategy involving glutamine restriction should be administered with caution. First, glutamine is an important nutrient for the human body, which limits the degree of glutamine reduction. Clinical trials utilizing Don have been abandoned for its serious side effects, especially unacceptable gastrointestinal toxicities [24]. In addition, perturbation of glutamine metabolism may provoke systemic metabolic compensation, which could have a complex effect on cancer progression [25]. For example, pancreatic cancer cells rescue the glutamine deprivation crisis by de novo biosynthesis using α-ketoglutarate (α-KG) from the TCA cycle, which is mediated by glutamate-ammonia ligase (GLUL) [14]. Therefore, balancing treatments and side effects and controlling intrinsic glutamine biosynthesis are the major tasks for the development of glutamine inhibitors in cancer management.
Pancreatic cancer exhibits extremely abundant desmoplasia, which is mainly derived from pancreatic stellate cells [3]. Pancreatic cancer cells usually reside in a barren microenvironment where nutrients and oxygen are scarce. One previous study showed that stroma served as a proline reservoir for glutamine and other nutrient production under nutrient deprivation conditions [26]. The interconversion among glutamine, proline, and collagen is mainly mediated by proline dehydrogenase 1 (PRODH1), which is necessary for pancreatic cancer cell growth. Our study indicates that a potential interconversion exists between glutamine and proline/stroma in pancreatic cancer. However, whether the abundant stroma promotes pancreatic cancer progression by supplying glutamine for tumor growth and CA19-9 production needs further study.
In conclusion, the above findings suggest that pancreatic cancer cells, which are different from their nontransformed counterparts, have a strong metabolic dependency on glutamine. Thus, glutamine addiction may serve as an appealing vulnerability for the treatment of pancreatic cancer.
4 Materials and methods
4.1 Patient data collection and ethics statement
Medical records were retrieved from a database constructed by the Fudan University Shanghai Cancer Center. Variables including age, sex, tumor location, metastatic status, size, CA19-9, lymphatic metastasis, and overall survival were retrieved. Pancreatic cancers were classified according to the 8th American Joint Committee on Cancer (AJCC) staging system. All pancreatic cancer tissue specimens were obtained from the Fudan University Shanghai Cancer Center, Shanghai, China. All patients were given informed consent, which was consented by the Institutional Review Board of the Fudan University Shanghai Cancer Center.
4.2 Animal protocols, diets, and treatment
Six-week-old athymic BALB/c nude mice (female) were obtained from Shanghai Jihui Laboratory Animal Co., Ltd. (Shanghai, China) and maintained under special pathogen-free (SPF) facilities with approved experimental protocols. None of the experiments exceeded the limits (2000 mm3) permitted by the IACUC of Fudan University. Experiments were performed in accordance with the institutional ethical guidelines and were approved by the institutional review board of Fudan University.
4.3 Cell lines and cell culture
BxPC-3, SU.8686, and SW1990 cells were purchased from American Type Culture Collection (ATCC). All the cells were kept in DMEM with 4.5 g/liter glucose supplemented with 10% FBS and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.). Cell lines were maintained in a 5% CO2 incubator at 37 °C. Cells used for the experimental study were passaged within 10 to 15 passages after reviving from the frozen vials. Cell lines were routinely tested to exclude Mycoplasma contamination. Cell proliferation was evaluated every 24 h using a Cell Counting Kit-8 (DOJINDO, Japan), according to the manufacturer’s instructions.
4.4 Immunofluorescence staining
For cell staining, cells grown on coverslips were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 in TBS (50 mM Tris–HCl, pH 7.4, 150 mM NaCl) buffer. For specimen staining, formalin-fixed, paraffin-embedded sections of pancreatic cancer tissues were obtained. After blocking with 5% BSA (Yeasen, Shanghai) in PBS, antibodies against O-GlcNAc (Abcam, Inc., ab2739) or CA19-9 (Abcam, Inc., ab3982) at a dilution of 1/200 in 5% BSA were used to detect their expression at 4 °C overnight. After washing, the samples were stained with AlexaFluor® 488 goat anti-rabbit secondary antibody (Jackson ImmunoResearch, Inc.) or AlexaFluor® 594 goat anti-mouse secondary antibody (Jackson ImmunoResearch, Inc.) at a 1/200 dilution for 1 h at room temperature. DAPI (Southern Biotech, Inc.) was used as the nuclear counterstain. Fluorescent images were acquired using a Leica confocal laser scanning microscope (Leica, Inc.). Confocal imaging was performed in seven random fields. Mean fluorescence intensity (MFI) was calculated using Image-Pro plus software (version 6.0, Media Cybernetics, Inc.).
4.5 Western blot and lectin blot analyses
Collected cells were incubated in RIPA buffer, 1 mM PMSF, and 1× Proteinase Inhibitor Cocktail (Beyotime, China) for 30 min. Diluted protein samples were added to 5 × SDS‒PAGE loading buffer and then heated at 100 °C for 10 min to denature proteins. Protein samples (10 μg) were loaded on a 10% SDS‒PAGE gel and run at 100 V for 80 min in SDS‒PAGE running buffer. After blocking with 5% skimmed milk in TBST, the blots were incubated with anti-CA19-9 antibody (Abcam, USA) in blocking solution on a shaker at 4 °C overnight. Blots were incubated with goat anti-mouse IgG (H + L)-HRP or goat anti-rabbit IgG (H + L)-HRP (Proteintech Group, USA) at 1:5,000 in TBST on a shaker at room temperature for 1 h.
For lectin blot analysis, biotinylated Aleuria aurantia lentin (AAL, 3 µg/ml), biotinylated Datura sodium lectin (DSL, 3 µg/ml), biotinylated Galanthus nivalis lectin (GNL, 3 µg/ml), biotinylated Phaseolus vulgaris leucoagglutinin (PHA-L, 3 µg/ml), biotinylated Phaseolus vulgaris erythroagglutinin (PHA-E, 3 µg/ml), and biotinylated wheat germ agglutinin (WGA, 5 µg/ml; Vector Laboratories, Inc.) were incubated with 3% BSA on a shaker for 30 min and then incubated with 0.1 µg/ml streptavidin-HRP conjugate (Vector Laboratories, Inc.) in blocking buffer for 20 min at room temperature [27]. Images were taken using a ChemiScope 3000 mini (CLiNX, Shanghai, China) after the Chemi Signal ECL Plus (CLiNX, China) reaction. The intensity of the blotting signals was measured by densitometric analysis using ImageJ.
4.6 Measurement of CA19-9 in fluids
For patients with pancreatic cancer, serum was collected at the time of diagnosis without major treatments. For mouse models, serum was collected at sacrifice. For cultured cells, supernatants were collected at predetermined times of cell culture. The concentration of CA19-9 in fluids was measured using an electrochemiluminescence immunoassay with a CA19-9 assay kit (Roche) on a Roche Cobase 8000 immunoassay analyzer (Roche Diagnostics, Mannheim, Germany) [28].
4.7 Subcutaneous animal models
The right flanks of mice were injected subcutaneously with 1 × 106 pancreatic cancer cells. Mice were randomly assigned to the Don group (750 mg/kg) or the control group (the same volume of saline). Drugs were administered intraperitoneally twice weekly after inoculation. Mice were observed twice weekly after inoculation. The size of xenografts was measured twice a week by measuring tumors with calipers. Tumor volumes were determined using the formula \({\text{volume }} = \, \left( {\text{long axis}} \right) \, \times \, \left( {\text{short axis}} \right)^{{2}} \times \, \pi /{6}\). At the indicated times, the tumors were surgically dissected and weighed. Samples were then processed for histopathologic examination.
4.8 Lymphatic metastasis models
The right nail pad of mice was injected subcutaneously with 1×106 pancreatic cancer cells [29]. Mice were randomly assigned to the Don group (750 mg/kg) or the control group (the same volume of saline). Drugs were administered intraperitoneally twice weekly after inoculation. Mice were observed twice weekly after inoculation. At the indicated times, the animals were euthanized, and the popliteal, inguinal, iliac and renal hilus lymph nodes were harvested to examine lymphatic metastasis. Metastatic lymph nodes were confirmed by H&E staining and pathological examination.
4.9 Intraperitoneal mouse models
Mice were injected intraperitoneally with 1×106 pancreatic cancer cells. Mice were randomly assigned to the Don group (750 mg/kg) or the control group (the same volume of saline). Drugs were administered intraperitoneally twice weekly after inoculation. Mice were observed twice weekly after inoculation. At the indicated times, the animals were euthanized, and the intraperitoneal metastases were harvested. Intraperitoneal implantation was confirmed by H&E staining and pathological examination.
4.10 UHPLC‒MS-based quantitative measurement of CA19-9
SU. 8686 and SW1990 pancreatic cancer cells were cultured for 72 h in L-glutamine-15N2 (Sigma‒Aldrich, 490032). Cells cultured in unlabeled glutamine (Sigma‒Aldrich, Cat.# G3126) were used as controls. A total of 1 × 107 cells were used for analysis. Before examination, a standard curve was built using 3'-Sialyl Lewis A (Carbosynth, Cat.# OS00745) diluted in methanol/water (1:1) at different concentrations (1, 5, 10, 50, 100, 500, 1000, 5000, 10000 nM). A total of 160 μL of methanol (precooled at − 20 °C) was added to each sample for metabolite extraction. Then, the samples were centrifuged at 18000 g and 4 °C for 20 min, and the clear supernatant was transferred to an autosampler vial for UHPLC‒MS/MS analysis. Ultra-performance liquid chromatography coupled to a tandem mass spectrometry system (ACQUITY UPLC I class-Xevo TQ-S system, Waters Corp., Milford, MA, USA) equipped with a Waters ACQUITY UPLC BEH Amide column (100 × 2.1 mm, 1.7 μm) was used to measure the metabolites. Mobile phase A was 10 mM ammonium acetate in water, and mobile phase B was acetonitrile. The elution gradient was set as follows: 0–1.0 min, 1% A; 1.0–3.0 min, 1–40% A; 3.0–5.0 min, 40% A; 5.0–5.1 min, 40–1% A; 5.1–6 min, 1% A. The injected volume was 5 μL. Data acquisition and metabolite quantification were performed using MassLynx 4.1 software (Waters Corp., Milford, MA, USA).
4.11 Label-free quantitative N-glycosylation proteomics
Proteins were extracted using SDT lysis buffer (4% SDS, 100 mM DTT, 100 mM Tris–HCl pH 8.0). Protein digestion was carried out using the FASP method described by Wisniewski et al. [30]. Four hundred micrograms of tryptic peptides was transferred to YM-30 filtration units and incubated for 1 h with a lectin mixture containing 90 µg ConA, 90 µg WGA and 90 µg RCA120 in 36 µl 2X binding buffer [31, 32]. LC‒MS/MS was performed on a Q Exactive Plus mass spectrometer coupled with Easy 1200 nLC (Thermo Fisher Scientific). The MS data were analyzed using MaxQuant software version 1.6.1.0. MS data were searched against the SwissProt human database (20431 total entries, downloaded 10/15/2019). Construction of protein–protein interaction (PPI) networks was also performed using the STRING database with Cytoscape software [33]. The Motif-X algorithm in the MEME Suite (MEME version 5.1.0) was used for N-linked glycosylation motif analysis [34].
4.12 Ultrahigh-performance liquid chromatography (UHPLC)-MS/MS
For metabolite extraction, 1000 μL of extract solvent (precooled at − 20 °C, acetonitrile-methanol–water, 2:2:1) was added to each sample, and the samples were vortexed for 30 s, homogenized at 45 Hz for 4 min, and sonicated for 5 min in an ice-water bath. UHPLC separation was performed using an Agilent 1290 Infinity II series UHPLC System (Agilent Technologies, Inc., Santa Clara, CA, USA) equipped with a Waters ACQUITY UPLC BEH Amide column (100 × 2.1 mm, 1.7 μm). An Agilent 6460 triple quadrupole mass spectrometer (Agilent Technologies, Inc., Santa Clara, CA, USA) equipped with an AJS electrospray ionization (AJS-ESI) interface was used for assay development. Agilent MassHunter Work Station Software (B.08.00, Agilent Technologies) was applied for MRM data acquisition and processing.
4.13 Isotope tracing untargeted metabolomics
SU. 8686 pancreatic cancer cells were cultured for 12 h or 24 h in L-glutamine-13C5 (2 mM, Cat. #605166, Sigma‒Aldrich) or L-glutamine-15N2 (Sigma‒Aldrich, 490032). Cells cultured in unlabeled glutamine (Sigma‒Aldrich, Cat.# G3126) were used as controls. A total of 1 × 107 cells were sent for analysis. Samples were prepared as previously described [35]. LC‒MS/MS analyses were performed using a UHPLC system (1290, Agilent Technologies) with a UPLC HSS T3 column (2.1 mm × 100 mm, 1.8 μm) coupled to a Q Exactive mass spectrometer (Thermo). Mobile phase A was 0.1% formic acid in water for positive mode and 5 mmol/L ammonium acetate in water for negative mode, and mobile phase B was acetonitrile. The elution gradient was set as follows: 0–1.0 min, 1% B; 1.0–8.0 min, 1–99% B; 8.0–10.0 min, 99% B; 10.0–10.1 min, 99–1% B; 10.1–12 min, 1% B. The flow rate was 0.5 mL/min. The raw data were converted to the mzXML format using ProteoWizard and processed with an in-house program, which was developed using R and based on XCMS, for peak detection, extraction, alignment, and integration [36]. Then, an in-house MS2 database (BiotreeDB) was applied for metabolite annotation. The cutoff for annotation was set at 0.3.
4.14 Statistical analysis
The statistical analyses were performed using SPSS 19.0 software (IBM Corp.) and Prism statistical software (version 8, GraphPad Software, Inc.). Paired 2-tailed Student’s t tests were used to examine the difference in glutamine concentration between primary pancreatic cancers and their matched metastases (liver or lymph node). Unpaired 2-tailed Student’s t tests were used to evaluate other data. For multiple comparisons, ANOVA combined with Bonferroni was applied. Data are presented as the mean ± standard error of the mean. Spearman correlation analysis was used to determine the correlation between glutamine concentration and other variables. Survival analysis was calculated by the Kaplan–Meier method, and the survival curves were examined by log-rank tests. Significance was defined as a p value < 0.05, unless otherwise stated.
Data availability
All other data needed to evaluate the conclusions in the paper are present in the paper. Data are available on request from the corresponding author.
Abbreviations
- Aza:
-
Azaserine; CA19-9: carbohydrate antigen 19–9
- coIP-MS:
-
Co-immunoprecipitation mass spectrometry
- Don:
-
Diazooxonorleucine
- GLUL:
-
Glutamate-ammonia ligase
- HBP:
-
Hexosamine biosynthetic pathway
- KEGG:
-
Kyoto encyclopedia of genes and genomes
- O-GlcNAc:
-
O-linked n-acetylglucosamine
- PDAC:
-
Pancreatic ductal adenocarcinoma
- PRODH:
-
Proline dehydrogenase 1
- UDP-GalNAc:
-
UDP-n-acetyl-D-galactosamine
- UDP-GlcNAc:
-
UDP-n-acetylglucosamine
- UHPLC–MS/MS:
-
Ultra-high performance liquid chromatography tandem mass spectrometry
References
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA A Cancer J Clin. 2021;71(1):7–33.
Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA A Cancer J Clin. 2013;63(5):318–48.
Gore J, Korc M. Pancreatic cancer stroma: friend or foe? Cancer Cell. 2014;25(6):711–2.
Liu W, Le A, Hancock C, Lane AN, Dang CV, Fan TW, Phang JM. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci USA. 2012;109(23):8983–8.
Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, Qian Y, Huang Q, Ni Q, Liu C, et al. Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter. Biochim Biophys Acta. 2021;1875(2): 188409.
Engle DD, Tiriac H, Rivera KD, Pommier A, Whalen S, Oni TE, Alagesan B, Lee EJ, Yao MA, Lucito MS, et al. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science. 2019;364(6446):1156–62.
Gebauer F, Wicklein D, Stubke K, Nehmann N, Schmidt A, Salamon J, Peldschus K, Nentwich MF, Adam G, Tolstonog G, et al. Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp–/rag2– mice. Gut. 2013;62(5):741–50.
Halbrook CJ, Lyssiotis CA. Employing metabolism to improve the diagnosis and treatment of pancreatic cancer. Cancer Cell. 2017;31(1):5–19.
Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Investig. 2013;123(9):3678–84.
Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16(10):619–34.
Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine metabolism in cancer: understanding the heterogeneity. Trends in cancer. 2017;3(3):169–80.
Qin C, Yang G, Yang J, Ren B, Wang H, Chen G, Zhao F, You L, Wang W, Zhao Y. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol Cancer. 2020;19(1):50.
Luo G, Liu C, Guo M, Cheng H, Lu Y, Jin K, Liu L, Long J, Xu J, Lu R, et al. Potential biomarkers in lewis negative patients with pancreatic cancer. Ann Surg. 2017;265(4):800–5.
Bott AJ, Shen J, Tonelli C, Zhan L, Sivaram N, Jiang YP, Yu X, Bhatt V, Chiles E, Zhong H, et al. Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism. Cell Reports. 2019;29(5):1287–98.
Xu R, Yang J, Ren B, Wang H, Yang G, Chen Y, You L, Zhao Y. Reprogramming of amino acid metabolism in pancreatic cancer: recent advances and therapeutic strategies. Front Oncol. 2020;10: 572722.
Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012;15(1):110–21.
Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science. 2001;291(5512):2376–8.
Slawson C, Hart GW. O-GlcNAc signalling: implications for cancer cell biology. Nat Rev Cancer. 2011;11(9):678–84.
Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol. 2012;13(7):448–62.
Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540–55.
Campbell S, Mesaros C, Izzo L, Affronti H, Noji M, Schaffer BE, Tsang T, Sun K, Trefely S, Kruijning S, et al. Glutamine deprivation triggers NAGK-dependent hexosamine salvage. eLife. 2021. https://doi.org/10.7554/eLife.62644.
Kanarek N, Petrova B, Sabatini DM. Dietary modifications for enhanced cancer therapy. Nature. 2020;579(7800):507–17.
Niklison-Chirou MV, Erngren I, Engskog M, Haglof J, Picard D, Remke M, McPolin PHR, Selby M, Williamson D, Clifford SC, et al. TAp73 is a marker of glutamine addiction in medulloblastoma. Genes Dev. 2017;31(17):1738–53.
Lemberg KM, Vornov JJ, Rais R, Slusher BS. We’re not “DON” yet: optimal dosing and prodrug delivery of 6-Diazo-5-oxo-L-norleucine. Mol Cancer Ther. 2018;17(9):1824–32.
Biancur DE, Paulo JA, Malachowska B, Quiles Del Rey M, Sousa CM, Wang X, Sohn ASW, Chu GC, Gygi SP, Harper JW, et al. Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nat Commun. 2017;8:15965.
Olivares O, Mayers JR, Gouirand V, Torrence ME, Gicquel T, Borge L, Lac S, Roques J, Lavaut MN, Berthezene P, et al. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat Commun. 2017;8:16031.
Liu C, Deng S, Jin K, Gong Y, Cheng H, Fan Z, Qian Y, Huang Q, Ni Q, Luo G, et al. Lewis antigennegative pancreatic cancer: an aggressive subgroup. Int J Oncol. 2020;56(4):900–8.
Luo G, Xiao Z, Long J, Liu Z, Liu L, Liu C, Xu J, Ni Q, Yu X. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. J GastrointesT Surg. 2013;17(12):2092–8.
Luo G, Yu X, Jin C, Yang F, Fu D, Long J, Xu J, Zhan C, Lu W. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm. 2010;385(1–2):150–6.
Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6(5):359–62.
Zielinska DF, Gnad F, Schropp K, Wisniewski JR, Mann M. Mapping N-glycosylation sites across seven evolutionarily distant species reveals a divergent substrate proteome despite a common core machinery. Mol Cell. 2012;46(4):542–8.
Yang Y, Zheng N, Wang W, Zhao X, Zhang Y, Han R, Ma L, Zhao S, Li S, Guo T, et al. N-glycosylation proteomic characterization and cross-species comparison of milk fat globule membrane proteins from mammals. Proteomics. 2016;16(21):2792–800.
Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol. 2011;696:291–303.
Cheng A, Grant CE, Noble WS, Bailey TL. MoMo: discovery of statistically significant post-translational modification motifs. Bioinformatics. 2019;35(16):2774–82.
Want EJ, Wilson ID, Gika H, Theodoridis G, Plumb RS, Shockcor J, Holmes E, Nicholson JK. Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc. 2010;5(6):1005–18.
Smith CA, Want EJ, O’Maille G, Abagyan R, Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem. 2006;78(3):779–87.
Acknowledgements
We thank Dr. Ziqi Chen from Shanghai Institute of Materia Medica, Prof. Changyou Zhan from Fudan University Shanghai Medical College, Dr. Cao Xie from School of Pharmacy, Fudan University for their assistance in mass spectrometry. We thank Prof. Yuhui Huang from Soochow University and Dr. Zhonghua Wu from Shanghai University of Traditional Chinese Medicine for their assistance in animal models. We thank Dr. Xianghuo He from Fudan University Shanghai Cancer Center and Dr. Zuqiang Liu from Zhongshan Hospital, Fudan University for technical assistance. We acknowledge the assistance of Fudan University Cancer Institute for flow cytometry and confocal microscope; Shanghai Biotree Biotech Co., Ltd. and Human Metabolomics Institute, Inc. for mass spectrometry; Shanghai Runnerbio Technology CO., Ltd for sirius red and masson’s trichrome staining; Shanghai bioprofile Co., Ltd. for co-immunoprecipitation-mass spectrometry and label-free quantitative proteomics; Fantastic Color Co., Ltd. for illustration designing; American Journal Experts (www.aje.com) for English language editing.
Funding
This work was supported by the National Natural Science Foundation of China (Grant Numbers 82072693, 81625016, 81871940, 81902417), the Scientific Innovation Project of Shanghai Education Committee (2019-01-07-00-07-E00057), Clinical and Scientific Innovation Project of Shanghai Hospital Development Center (SHDC12018109), the Shanghai Cancer Center Foundation for Distinguished Young Scholars (Grant Number YJJQ201803), and the Fudan University Personalized Project for “Double Top” Original Research (Grant Number XM03190633).
Author information
Authors and Affiliations
Contributions
Conceptualization, GL, XY and WW; Methodology, CL, SD, RL, GL, XY and WW; Validation, CL, SD, RL, QX and GL; Formal Analysis, CL, SD, QX and GL; Investigation, GL, XY and WW; Resources, CL, SD, and GL; Data Curation, CL, SD, RL, HC, JF, XS, and ZX; Writing—Original Draft, GL, XY and WW; Writing—Review & Editing, GL, XY and WW; Visualization, GL, XY and WW; Supervision, GL, QX, XY and WW; Project Administration, GL, QX and XY; Funding Acquisition, GL, CL, H.C., and XY. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
All patients provided informed consent, which was approved by the Institutional Review Board of the Fudan University Shanghai Cancer Center (Approval No. 050432-4-1911D; 2008222-16). Written informed consent was obtained for participation in this study. Animal experiments were performed in accordance with the institutional ethical guidelines and were approved by the institutional review board of Fudan University (Approval No. FUSCC-IACUC-S20210186).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Liu, C., Deng, S., Xiao, Z. et al. Glutamine is a substrate for glycosylation and CA19-9 biosynthesis through hexosamine biosynthetic pathway in pancreatic cancer. Discov Onc 14, 20 (2023). https://doi.org/10.1007/s12672-023-00628-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12672-023-00628-z